These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 1537382)

  • 21. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity.
    Liew FY; Russell SM; Appleyard G; Brand CM; Beale J
    Eur J Immunol; 1984 Apr; 14(4):350-6. PubMed ID: 6609824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral proteins.
    Ze C; Kurata T; Tamura S
    Jpn J Infect Dis; 2000 Dec; 53(6):219-28. PubMed ID: 11227019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies on the usefulness of intranasal inactivated influenza vaccines.
    Tamura S
    Vaccine; 2010 Aug; 28(38):6393-7. PubMed ID: 20493820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.
    Lee KH; Seo SU; Song JM; Lee CM; Kim HA; Seong BL
    Vaccine; 2006 Mar; 24(11):1966-74. PubMed ID: 16343703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccines combined with cholera toxin B subunit.
    Tamura S; Kurata H; Funato H; Nagamine T; Aizawa C; Kurata T
    Vaccine; 1989 Aug; 7(4):314-20. PubMed ID: 2815967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
    Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
    Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection against lethal influenza virus encephalitis by intranasally primed CD8+ memory T cells.
    Stevenson PG; Hawke S; Bangham CR
    J Immunol; 1996 Oct; 157(7):3065-73. PubMed ID: 8816416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
    Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
    de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
    J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations.
    Furuya Y; Regner M; Lobigs M; Koskinen A; Müllbacher A; Alsharifi M
    J Gen Virol; 2010 Jun; 91(Pt 6):1450-60. PubMed ID: 20147516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness.
    Bizanov G; Janakova L; Knapstad SE; Karlstad T; Bakke H; Haugen IL; Haugan A; Samdal HH; Haneberg B
    Scand J Immunol; 2005 Jun; 61(6):503-10. PubMed ID: 15963044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
    Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit.
    Tamura S; Samegai Y; Kurata H; Nagamine T; Aizawa C; Kurata T
    Vaccine; 1988 Oct; 6(5):409-13. PubMed ID: 2848377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine.
    Vincent AL; Lager KM; Janke BH; Gramer MR; Richt JA
    Vet Microbiol; 2008 Jan; 126(4):310-23. PubMed ID: 17719188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
    Wu F; Yuan XY; Huang WS; Chen YH
    Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein.
    Guo L; Zheng M; Ding Y; Li D; Yang Z; Wang H; Chen Q; Sui Z; Fang F; Chen Z
    Arch Virol; 2010 Nov; 155(11):1765-75. PubMed ID: 20652335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.